Emergent Biosolutions Inc (EBS) : Insight Capital Research Management Inc reduced its stake in Emergent Biosolutions Inc by 2.42% during the most recent quarter end. The investment management company now holds a total of 203,367 shares of Emergent Biosolutions Inc which is valued at $8,026,895 after selling 5,052 shares in Emergent Biosolutions Inc , the firm said in a disclosure report filed with the SEC on May 10, 2016.Emergent Biosolutions Inc makes up approximately 2.50% of Insight Capital Research Management Inc’s portfolio.
Other Hedge Funds, Including , Schwab Charles Investment Management Inc reduced its stake in EBS by selling 60,305 shares or 10.26% in the most recent quarter. The Hedge Fund company now holds 527,351 shares of EBS which is valued at $20,197,543. Emergent Biosolutions Inc makes up approx 0.03% of Schwab Charles Investment Management Inc’s portfolio.Rice Hall James Associates boosted its stake in EBS in the latest quarter, The investment management firm added 5,746 additional shares and now holds a total of 275,297 shares of Emergent Biosolutions Inc which is valued at $10,604,440. Emergent Biosolutions Inc makes up approx 0.62% of Rice Hall James Associates’s portfolio. Sawtooth Asset Management sold out all of its stake in EBS during the most recent quarter. The investment firm sold 26,204 shares of EBS which is valued $1,009,378.Glenmede Trust Co Na reduced its stake in EBS by selling 40,531 shares or 5.14% in the most recent quarter. The Hedge Fund company now holds 748,557 shares of EBS which is valued at $28,834,416. Emergent Biosolutions Inc makes up approx 0.19% of Glenmede Trust Co Na’s portfolio.
Emergent Biosolutions Inc opened for trading at $39.55 and hit $41.09 on the upside on Monday, eventually ending the session at $40.84, with a gain of 3.47% or 1.37 points. The heightened volatility saw the trading volume jump to 7,85,515 shares. Company has a market cap of $1,636 M.
On the company’s financial health, Emergent Biosolutions Inc reported $0.16 EPS for the quarter, beating the analyst consensus estimate by $ 0.28 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.12. The company had revenue of $111.00 million for the quarter, compared to analysts expectations of $107.57 million. The company’s revenue was up 74.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.50 EPS.
Many Wall Street Analysts have commented on Emergent Biosolutions Inc. Chardan Capital Markets Initiated Emergent Biosolutions Inc on Apr 15, 2016 to “Buy”, Price Target of the shares are set at $47.Singular Research Initiated Emergent Biosolutions Inc on Mar 28, 2016 to “Buy”, Price Target of the shares are set at $44.Emergent Biosolutions Inc was Initiated by Wells Fargo to “Outperform” on Feb 19, 2016.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Company’s two operating divisions include Biodefense and Biosciences. The Company’s Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical Biological Radiological Nuclear and Explosives) threats. The Biodefense division’s marketed products are BioThrax; BAT; Anthrasil; VIGIV and RSDL. The Biodefense division investigational stage product candidates include NuThrax PreviThrax GC-072 and other biodefense product candidates. The Biosciences division’s marketed products are WinRho SDF HepaGam B VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY ES414 and otlertuzumab.